| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Basic Science Investigations |
1 Department of Radiology, Duke University Medical Center, Durham, North Carolina
2 Division of Radiation Safety, Duke University Medical Center, Durham, North Carolina
3 Department of Surgery, Duke University Medical Center, Durham, North Carolina
18F-Fluorocholine (fluoromethyl-dimethyl-2-hydroxyethylammonium [FCH]) has been developed as an oncologic probe for PET. This study evaluates the kinetics and radiation dosimetry of 18F-FCH using murine and human biodistribution data. Methods: The biodistribution of 18F-FCH was obtained at time points up to 10 h after administration in control and tumor-bearing anesthetized nude mice. Human biodistribution data within the first hour after injection were obtained from attenuation-corrected whole-body PET scans of male (n = 7) and female (n = 5) cancer patients. Radiation dosimetry estimates were calculated using the murine and human biodistribution data assuming no redistribution of tracer after 1 h. Results: Rapid pharmacokinetics were observed for 18F-FCH in mice and humans. The biodistribution is nearly static after 10 min. The dose-critical organ is the kidney, which receives 0.17 ± 0.05 and 0.16 ± 0.07 mSv/MBq (0.64 ± 0.18 and 0.55 ± 0.32 rad/mCi) for females and males, respectively. The effective dose equivalent (whole body) from administration of 4.07 MBq/kg (0.110 mCi/kg) is approximately 0.01 Sv for females and males. Conclusion: 18F-FCH is rapidly cleared from the circulation and its biodistribution changes very slowly at >10 min after administration. The kidney is the dose-critical organ and limits administration levels of 18F-FCH to 4.07 MBq/kg (0.110 mCi/kg) in human research studies.
Key Words: 18F-fluorocholine • PET • oncology
This article has been cited by other articles:
|
|
 |
|
  J. Leyton, G. Smith, Y. Zhao, M. Perumal, Q.-D. Nguyen, E. Robins, E. Arstad, and E. O. Aboagye [18F]Fluoromethyl-[1,2-2H4]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography Cancer Res., October 1, 2009; 69(19): 7721 - 7728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shanehsazzadeh, A. R. Jalilian, H. R. Sadeghi, and M. Allahverdi Determination of human absorbed dose of 67GA-DTPA-ACTH based on distribution data in rats Radiat Prot Dosimetry, June 1, 2009; 134(2): 79 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Apolo, N. Pandit-Taskar, and M. J. Morris Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer J. Nucl. Med., December 1, 2008; 49(12): 2031 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. DeGrado, S. A. Kwee, M. N. Coel, and R. E. Coleman The Impact of Urinary Excretion of 18F-Labeled Choline Analogs J. Nucl. Med., July 1, 2007; 48(7): 1225 - 1225. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Kwee, H. Wei, I. Sesterhenn, D. Yun, and M. N. Coel Localization of Primary Prostate Cancer with Dual-Phase 18F-Fluorocholine PET J. Nucl. Med., February 1, 2006; 47(2): 262 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Reubi, H. R. Macke, and E. P. Krenning Candidates for Peptide Receptor Radiotherapy Today and in the Future J. Nucl. Med., January 1, 2005; 46(1_suppl): 67S - 75S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Applegate, R. Tello, and J. Ying Hypothesis Testing III: Counts and Medians Radiology, September 1, 2003; 228(3): 603 - 608. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
